Considering the SHP2 structural and functional properties (described in paragraph 4.1), the possibility of pharmacologically stabilizing the autoinhibited conformation to block the cellular signaling became an attractive approach to fighting several types of cancers [136] or syndromes (e.g., Noonan syndrome) [95]. This evidence concerns the gene PTPN11 and Noonan syndrome.